| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JHEP.2010.07.009 |
| P953 | full work available online at | https://api.elsevier.com/content/article/PII:S0168827810007798?httpAccept=text/xml |
| https://api.elsevier.com/content/article/PII:S0168827810007798?httpAccept=text/plain | ||
| P698 | PubMed publication ID | 21095036 |
| P2093 | author name string | Andrea M. Woltman | |
| Harry L. A. Janssen | |||
| Eric T. T L. Tjwa | |||
| Gertine W. van Oord | |||
| Joost P. Hegmans | |||
| P2860 | cites work | Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells | Q24675226 |
| CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor | Q78127360 | ||
| Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming | Q80975562 | ||
| Functions of natural killer cells | Q29614300 | ||
| Up on the tightrope: natural killer cell activation and inhibition | Q29619175 | ||
| CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets | Q33597507 | ||
| Natural killer cells in antiviral defense: function and regulation by innate cytokines | Q33652468 | ||
| Accessory cell dependent NK cell mediated PBMC IFN-gamma production is defective in HIV infection | Q34020126 | ||
| Noncytolytic control of viral infections by the innate and adaptive immune response | Q34178107 | ||
| The biology of human natural killer-cell subsets | Q34430869 | ||
| PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. | Q34583193 | ||
| Kinetics of the immune response during HBV and HCV infection. | Q35164171 | ||
| Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection. | Q35670114 | ||
| Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. | Q35760543 | ||
| IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2. | Q35847866 | ||
| Interplay of natural killer cells and their receptors with the adaptive immune response | Q35904393 | ||
| Different checkpoints in human NK-cell activation | Q35941923 | ||
| Pathogen-induced private conversations between natural killer and dendritic cells. | Q36057673 | ||
| Evidence for discrete stages of human natural killer cell differentiation in vivo | Q36228536 | ||
| Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage | Q36267204 | ||
| Human natural killer cells | Q36787596 | ||
| New aspects of NK cell subset identification and inference of NK cells' regulatory capacity by assessing functional and genomic profiles | Q37136148 | ||
| EASL Clinical Practice Guidelines: management of chronic hepatitis B. | Q37340737 | ||
| Immunology of hepatitis B and hepatitis C virus infections. | Q37383761 | ||
| Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels? | Q37653078 | ||
| Hepatitis B virus immunopathogenesis | Q40444875 | ||
| Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection | Q40495332 | ||
| Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms | Q40790742 | ||
| HIV infection is associated with a preferential decline in less-differentiated CD56dim CD16+ NK cells | Q41865397 | ||
| CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta | Q42078161 | ||
| Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset | Q43600819 | ||
| Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections | Q43713361 | ||
| Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. | Q43836377 | ||
| Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals | Q45006277 | ||
| Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. | Q45377151 | ||
| Early kinetics of innate and adaptive immune responses during hepatitis B virus infection | Q45386706 | ||
| Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells | Q45401996 | ||
| CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection | Q45609955 | ||
| A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. | Q46981468 | ||
| Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection | Q56951258 | ||
| Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms | Q57106837 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | viral load | Q2528140 |
| lymphocyte activation | Q22295739 | ||
| chronic hepatitis B | Q55779876 | ||
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 209-218 | |
| P577 | publication date | 2010-09-06 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B | |
| P478 | volume | 54 |
| Q33919051 | A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection. |
| Q52654932 | ADCC-Mediated CD56DIM NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection |
| Q56898617 | Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B |
| Q38008347 | Activation of Natural Killer Cells during Microbial Infections |
| Q42182803 | Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). |
| Q36101272 | Altered Immune Profiles of Natural Killer Cells in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis |
| Q26830435 | Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon |
| Q36487681 | Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients. |
| Q47561111 | Current concepts on immunopathogenesis of hepatitis B virus infection. |
| Q38283963 | Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections |
| Q35092599 | Decreased peripheral natural killer cells activity in the immune activated stage of chronic hepatitis B. |
| Q35111394 | Defective natural killer cell anti-viral capacity in paediatric HBV infection |
| Q33671963 | Different antiviral effects of IFNα subtypes in a mouse model of HBV infection. |
| Q35758694 | Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1+ Immune Cells |
| Q44781111 | Dissecting the divergent effects of interferon-alpha on immune cells: Time to rethink combination therapy in chronic hepatitis B? |
| Q34262225 | Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen. |
| Q40245207 | Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hep |
| Q59357110 | Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study) |
| Q90484385 | Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection |
| Q33652113 | Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. |
| Q36318152 | Frequency and role of NKp46 and NKG2A in hepatitis B virus infection. |
| Q40150197 | Functional restoration of CD56(bright) NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B. |
| Q48576315 | HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo |
| Q64078769 | Hepatic Natural Killer Cells: Organ-Specific Sentinels of Liver Immune Homeostasis and Physiopathology |
| Q33559657 | Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies |
| Q33796676 | Hepatitis B Virus Lacks Immune Activating Capacity, but Actively Inhibits Plasmacytoid Dendritic Cell Function |
| Q36281598 | Hepatitis B Virus-Related Hepatocellular Carcinoma: Pathogenic Mechanisms and Novel Therapeutic Interventions |
| Q37892655 | Hepatitis B surface antigen monitoring and management of chronic hepatitis B |
| Q45360463 | Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells |
| Q57160343 | Hepatitis B virus-persistent infection and innate immunity defect: Cell-related or virus-related? |
| Q92104140 | Hepatocellular carcinoma: Mechanisms of progression and immunotherapy |
| Q38740771 | Host-virus interactions in hepatitis B and hepatitis C infection |
| Q38383489 | How to achieve immune control in chronic hepatitis B? |
| Q39327457 | Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection |
| Q64083350 | Immune response pattern varies with the natural history of chronic hepatitis B |
| Q36073739 | Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections |
| Q37946440 | Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection |
| Q38262108 | Immunopathogenesis of chronic hepatitis B. |
| Q38186180 | Innate immune responses in hepatitis B virus (HBV) infection |
| Q26743647 | Innate immune targets of hepatitis B virus infection |
| Q27318089 | Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B |
| Q40752122 | Involvement of LSECtin in the hepatic natural killer cell response. |
| Q54217690 | Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? |
| Q33588171 | Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection |
| Q41919609 | Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B |
| Q40077350 | Mechanisms of Hepatitis B Virus Persistence |
| Q27001052 | NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma |
| Q43237496 | NK cells: a double-edged sword in chronic hepatitis B virus infection. |
| Q59795771 | Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications |
| Q34505690 | Natural Killer Cells in Viral Hepatitis |
| Q35751024 | Natural Killer p46 Controls Hepatitis B Virus Replication and Modulates Liver Inflammation |
| Q38527482 | Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy |
| Q42274457 | Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? |
| Q38964920 | Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. |
| Q52314600 | Natural killer cells in liver diseases |
| Q35786326 | Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells |
| Q33734554 | Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients |
| Q40050440 | Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection. |
| Q35868037 | Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection |
| Q38121579 | Reversal of hepatitis B virus‐induced systemic immune tolerance by intrinsic innate immune stimulation |
| Q90607894 | Role of alcohol in pathogenesis of hepatitis B virus infection |
| Q58080642 | Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase |
| Q34205905 | TGF-β1 Down-Regulation of NKG2D/DAP10 and 2B4/SAP Expression on Human NK Cells Contributes to HBV Persistence |
| Q26774875 | The Role of Immune Cells in Chronic HBV Infection |
| Q45326334 | The impact of KIR-HLA genotype on hepatitis B virus clearance in Iranian infected individuals |
| Q38027754 | The role of innate immunity in HBV infection |
| Q38219409 | The role of natural killer cells and CD8(+) T cells in hepatitis B virus infection |
| Q45325450 | Veritable antiviral capacity of natural killer cells in chronic HBV infection: an argument for an earlier anti-virus treatment |
Search more.